首页> 外文期刊>Journal of Renin-Angiotensin-Aldosterone System >Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy
【24h】

Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy

机译:厄贝沙坦治疗可能改善阿霉素诱发的肾病大鼠的缝隙隔膜改变

获取原文
           

摘要

The study aimed to evaluate the effects of oral administration of irbesartan in adriamycin-induced nephropathy considering laboratory changes, kidney histology, and expression of proteins related to slit diaphragm and cytoskeleton of the podocyte. The animals were divided into control, model, methylprednisolone (MP), and irbesartan groups. The 24-hour urinary protein and biochemical indicators were determined, and renal pathological changes were observed. The mRNA and protein expression of nephrin, podocin, CD2-associated protein (CD2AP), and desmin in the kidney tissue were analyzed. The urinary protein excretion levels in the MP and irbesartan groups were lower than those in the model group (p p p For rats with adriamycin-induced nephropathy, irbesartan could significantly reduce proteinuria. As a possible mechanism, irbesartan may improve the slit diaphragm protein of the glomerular podocyte and stabilize the cytoskeleton of the podocyte.
机译:该研究旨在评估厄贝沙坦口服对阿霉素引起的肾病的影响,考虑实验室变化,肾脏组织学以及与裂隙膜和足细胞细胞骨架相关的蛋白质表达。将动物分为对照组,模型组,甲基强的松龙(MP)和厄贝沙坦组。测定24小时尿蛋白和生化指标,观察肾脏病理变化。分析了肾组织中nephrin,podocin,CD2相关蛋白(CD2AP)和结蛋白的mRNA和蛋白表达。 MP组和厄贝沙坦组的尿蛋白排泄水平低于模型组(ppp对于患有阿霉素肾病的大鼠,厄贝沙坦可显着降低蛋白尿。厄贝沙坦可能是一种改善肾小球裂隙膜蛋白的机制足细胞并稳定足细胞的细胞骨架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号